Combination therapy in hypertension: An update

被引:0
作者
Sanjay Kalra
Bharti Kalra
Navneet Agrawal
机构
[1] Bharti Hospital,Dept of Endocrinology
[2] Bharti Hospital,Dept of Gynaecology
[3] GR Medical College,Dept of Medicine
来源
Diabetology & Metabolic Syndrome | / 2卷
关键词
Chronic Heart Failure; Amlodipine; Carvedilol; Felodipine; Candesartan;
D O I
暂无
中图分类号
学科分类号
摘要
Meticulous control of blood pressure is required in patients with hypertension to produce the maximum reduction in clinical cardiovascular end points, especially in patients with comorbidities like diabetes mellitus where more aggressive blood pressure lowering might be beneficial. Recent clinical trials suggest that the approach of using monotherapy for the control of hypertension is not likely to be successful in most patients. Combination therapy may be theoretically favored by the fact that multiple factors contribute to hypertension, and achieving control of blood pressure with single agent acting through one particular mechanism may not be possible. Regimens can either be fixed dose combinations or drugs added sequentially one after other. Combining the drugs makes them available in a convenient dosing format, lower the dose of individual component, thus, reducing the side effects and improving compliance. Classes of antihypertensive agents which have been commonly used are angiotensin receptor blockers, thiazide diuretics, beta and alpha blockers, calcium antagonists and angiotensin-converting enzyme inhibitors. Thiazide diuretics and calcium channel blockers are effective, as well as combinations that include renin-angiotensin-aldosterone system blockers, in reducing BP. The majority of currently available fixed-dose combinations are diuretic-based. Combinations may be individualized according to the presence of comorbidities like diabetes mellitus, chronic renal failure, heart failure, thyroid disorders and for special population groups like elderly and pregnant females.
引用
收藏
相关论文
共 447 条
[1]  
Ong KL(2010)Standards of medical care in diabetes Diabetes Care 33 11-61
[2]  
Cheung BM(2007)Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004 Hypertension 49 69-75
[3]  
Man YB(2002)Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies Lancet 360 1903-1913
[4]  
Lau CP(1998)Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial Lancet 351 1755-1762
[5]  
Lam KS(1995)Implications of small reductions in diastolic blood pressure for primary prevention Arch Intern Med 155 701-709
[6]  
Lewington S(2007)Emerging Insights in the First-Step Use of Antihypertensive Combination Therapy J Clin Hypertens (Greenwich) 9 5-14
[7]  
Clarke R(2007)Hypertension management: results of a new national survey for the hypertension education foundation: Harris interactive J Clin Hypertens (Greenwich) 9 316-323
[8]  
Qizilbash N(1995)Losartan potassium as initial therapy in patients with severe hypertension J Hum Hypertens 9 861-867
[9]  
Peto R(1998)Candesartan cilexetil enhances blood pressure reduction severe (state 3, JNC-VI) hypertensive patients inadequately controlled with HCTZ Am J Hypertens 11 121A-1615
[10]  
Collins R(1997)Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension Am J Cardiol 80 1613-567